Wolf‐Dietrich Doecke

Author

Charité - Universitätsmedizin Berlin

Also Known As

Asadullah, K, W.-D. Doecke, Wolf-Dietrich Doecke, Wolf‐Dietrich Doecke

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Bayer (Germany)Comprehensive Cancer Center Mainfranken Amgen (Germany)Universitätsklinikum Würzburg

About

Wolf‐Dietrich Doecke is an author at Charité - Universitätsmedizin Berlin specializing in medicine, inflammation, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1.1K
2	Immunology	4	4	502
3	Health Sciences	1	1	25
4	Emergency Medicine	1	1	600
5	Gastroenterology	1	1	263

Wolf‐Dietrich Doecke

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Immunologic and Hemodynamic Effects of “Low-Dose” Hydrocortisone in Septic Shock Didier Keh, T Boehnke, Steffen Weber‐Carstens, American Journal of Respiratory and Critical Care Medicine InflammationHypertensionHeart FailureAnti-inflammatoryCardiogenic Shock	2003	600
IL-22 Induces Lipopolysaccharide-Binding Protein in Hepatocytes: A Potential Systemic Role of IL-22 in Crohn’s Disease Kerstin Wolk, Ellen Witte, Ute Hoffmann, The Journal of Immunology Chronic Inflammatory DiseasesImmunologyGastroenterologyPathologyImmune Regulation	2007	263
Interleukin (IL)‐19, IL‐20 and IL‐24 are produced by and act on keratinocytes and are distinct from classical ILs Stefanie Kunz, Kerstin Wolk, Ellen Witte, Experimental Dermatology	2006	234
IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis Ellen Witte, Georgios Kokolakis, Katrin Witte, Journal of Investigative Dermatology InflammationCytokineMedicinePathogenetic Il-23/il-17 CascadeImmune Regulation	2014	158
Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts Nicolle Sitte, Michael Huber, Tilman Grune, The FASEB Journal	2000	140
Standardized immune monitoring for the prediction of infections after cardiopulmonary bypass surgery in risk patients Jens‐Christian Strohmeyer, Christian Meisel, Wolf‐Dietrich Doecke, Cytometry Part B Clinical Cytometry	2003	74
Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, Journal of Clinical Oncology Mcrpc PtsGenitourinary CancerMedicineImmunologyTumor Immunity	2019	56
Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, Journal of Clinical Oncology Bispecific T-cell EngagerImmunologyImmunoeditingBite Immune TherapyImmunotherapeutics	2020	25
Endometriosis Leads to an Increased Trefoil Factor 3 Concentration in the Peritoneal Cavity but Does Not Alter Systemic Levels Diana Henze, Wolf‐Dietrich Doecke, Daniela Hornung, Reproductive Sciences InflammationUterine FibroidsPeritoneal CavityUterine ReceptivityGynecology	2016	11
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2) Julia Huetter, Uwe Gritzan, Ilona Gutcher, Cancer Immunology Research	2020	11

Page 1